Institute of Medicine

Board on Health Care Services

Board on Health Sciences Policy

Committee on the Review of Omics-Based Tests for Predicting Patient Outcomes in Clinical Trials

Technologies collectively called omics enable simultaneous measurement of an enormous number of biomolecules; for example, genomics investigates thousands of DNA sequences, and proteomics examines large numbers of proteins. Scientists are using these technologies to develop innovative tests to detect disease and to predict a patient's likelihood of responding to specific drugs. Following a recent case involving premature use of omics-based tests in cancer clinical trials at Duke University, the NCI requested that the IOM establish a committee to recommend ways to strengthen omics-based test development and evaluation. This report identifies best practices to enhance development, evaluation, and translation of omics-based tests while simultaneously reinforcing steps to ensure that these tests are appropriately assessed for scientific validity before they are used to guide patient treatment in clinical trials.

Committee on the Review of Omics-Based Tests for Predicting Patient Outcomes in Clinical Trials

Books

Your next favorite book is out there